Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Rhea-AI Summary

Bio‑Techne (NASDAQ: TECH) and Refeyn launched an integrated workflow that links MauriceFlex™ icIEF fractionation with TwoMP mass photometry for bispecific antibody and biosimilar analysis.

The four‑hour process directly correlates charge variants with size and aggregation using nanogram‑level samples, aiming to cut development risk and speed biosimilar manufacturing.

News Market Reaction – TECH

+4.58%

+4.58% Session close to close

In the Jun 4 session, TECH gained 4.58%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a joint workflow from Bio‑Techne and Refeyn that links icIEF fractionat...

Analysis

This announcement highlights a joint workflow from Bio‑Techne and Refeyn that links icIEF fractionation with mass photometry to characterize bispecific antibodies and biosimilars in about 4 hours. It targets development risk and efficiency in a complex, fast‑growing biologics segment. In recent quarters, Bio‑Techne has focused on mixed but improving profitability metrics and brand simplification. Investors may watch for evidence of adoption, any revenue commentary tied to this platform, and how it complements existing Protein Sciences and Diagnostics growth initiatives.

Key Figures

Workflow duration: 4-hour workflow Conference dates: May 31 – June 4, 2026

2 metrics

Workflow duration 4-hour workflow Time to complete integrated icIEF–mass photometry characterization

Conference dates May 31 – June 4, 2026 ASMS conference presentation window for the new workflow

Historical Context

5 past events · Latest: May 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Dividend declaration	Positive	-16.4%	Quarterly dividend of $0.08 per share alongside scale of operations.
May 06	Earnings results	Neutral	-16.4%	Q3 FY2026 results with lower sales but sharply higher GAAP profitability.
May 04	Conference appearance	Neutral	-0.5%	Planned presentation at Bank of America Global Healthcare Conference.
Apr 16	Brand architecture update	Positive	-1.9%	Launch of streamlined portfolio brands across discovery to diagnostics.
Apr 14	Earnings call notice	Neutral	+2.0%	Announcement of date and access details for Q3 FY2026 call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent dividend and earnings announcements with improved GAAP metrics coincided with a -16.36% move, indicating selling pressure on financial updates even when profitability improved.

Recent Company History

Over the past few months, Bio‑Techne reported mixed Q3 FY2026 results with net sales of $311.4 million, down 2%, but GAAP EPS rising to $0.32 and operating margin improving to 24.2%, which nonetheless coincided with a -16.36% reaction. The company also declared a $0.08 quarterly dividend and refined its brand architecture into R&D Systems, Bio‑Techne Spatial, and Bio‑Techne Diagnostics. Conference appearances and earnings‑call logistics have produced relatively small price moves. Today’s product‑workflow announcement fits into a pattern of operational and portfolio positioning initiatives following the recent financial reset.

Key Terms

bispecific antibodies, biosimilars, mass photometry, imaged capillary isoelectric focusing, +2 more

6 terms

bispecific antibodies medical

"charge and size variants in bispecific antibodies and biosimilars."

Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.

biosimilars medical

"charge and size variants in bispecific antibodies and biosimilars."

Biosimilars are medicines made to be highly similar to an already approved biological drug produced from living cells, with no meaningful differences in safety or effectiveness. They matter to investors because they introduce lower‑cost competition to expensive biologic treatments—similar to how generic drugs compete with brand drugs—but involve more complex manufacturing, regulatory review and patent risk, which can affect market share, pricing and profit margins across the sector.

mass photometry technical

"Bio‑Techne and Refeyn, the pioneer in mass photometry technology, today announced"

A laboratory technique that measures the weight of individual proteins and other biomolecules by detecting tiny changes in light as each particle lands on a surface. Think of it as “weighing” single molecules by their subtle shadow, which helps scientists confirm a drug candidate’s composition, purity and how molecules assemble. Investors care because accurate, fast measurement reduces development risk, shortens timelines and improves quality control in biopharma R&D.

imaged capillary isoelectric focusing technical

"MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system"

Imaged capillary isoelectric focusing is a laboratory method that separates proteins or other charged molecules inside a thin tube by letting each molecule migrate to the point where its net electrical charge is zero, while a camera-like detector records where they settle—think of watching beads drift to different spots along a narrow tube and photographing their final positions. Investors should care because this precise, visual test is used in drug development, quality control and biomarker work to verify purity and consistency; clear, reproducible results can lower regulatory and product risk.

aggregation technical

"direct characterization of aggregation and size within icIEF-resolved charge variants"

Aggregation is the process of collecting and combining multiple items—such as data points, transactions, assets, or reports—into a single, summarized whole. For investors it matters because aggregation reveals scale and trends, boosts efficiency or market reach (like bundling small loans into one package), and can change risk, revenue and valuation profiles by turning many small pieces into one easier-to-evaluate item.

single‑molecule resolution technical

"aggregation at single‑molecule resolution in a streamlined four‑hour workflow."

The ability to see or measure one individual molecule at a time using specialized instruments or tests. Investors should care because this level of sensitivity can enable earlier disease detection, more precise drug measurements and lower sample sizes—like counting single grains of sand instead of estimating the beach—potentially improving diagnostic accuracy, speeding R&D, reducing costs, and creating products with stronger commercial or regulatory value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• New integrated workflow combines icIEF fractionation and mass photometry
• Enables direct characterization of aggregation and size within icIEF-resolved charge variants
• Four-hour workflow reduces development risk and accelerates biosimilar manufacturing

MINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.

By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single‑molecule resolution in a streamlined four‑hour workflow.

Bispecific antibodies are among the fastest-growing classes of biotherapeutics, but their structural complexity makes thorough characterization challenging. Incomplete characterization can delay development, increase manufacturing risk, and lead to costly late‑stage failures.

The MauriceFlex™ system delivers high-resolution separation and fractionation of charge variants, a capability increasingly expected in regulatory submissions. However, analyzing the size and aggregation of individual charge fractions has historically been difficult due to the large sample requirements of traditional methods.

The integrated workflow addresses this challenge directly by pairing icIEF fractionation with mass photometry. Charge variants are first separated using MauriceFlex™, then analyzed on Refeyn's TwoMP platform, which requires only nanogram‑level sample and reveals size distribution and aggregation at single‑molecule resolution.

Together, the technologies enable direct characterization of aggregation and size within icIEF-resolved charge variants—an insight not accessible with standalone methods—reducing reliance on multiple tests and enabling faster, more efficient process development.

"Bispecifics are the fastest growing segment within next‑generation antibodies, but they are very difficult to characterize. This approach directly addresses one of the biggest challenges by combining icIEF fractionation with mass photometry. Researchers can now interrogate charge and size variants together in a single workflow," said Gerry Mackay, CEO of Refeyn.

"Our customers are under intense pressure to develop and manufacture increasingly complex biologics faster and more efficiently. Enabling deeper characterization with less sample helps them reduce risk, control costs, and make better decisions earlier in development," said Will Geist, President Bio‑Techne Protein Sciences Segment.

In a joint webinar, scientists demonstrated the workflow using Mosunetuzumab‑axgb and a biosimilar, tracking size-related changes in the molecule across charge variant fractions under multiple conditions. An application note with full findings is available here.

The workflow will also be presented at the American Society for Mass Spectrometry (ASMS) conference, taking place May 31 – June 4, 2026, in San Diego. See booth and poster details here

ABOUT BIO‑TECHNE

Bio‑Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high‑quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer‑focused brands: R&D Systems™, Bio‑Techne Spatial™, and Bio‑Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio‑Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.

For more information on Bio‑Techne, please visit www.bio-techne.com or follow the company on LinkedIn, X, or YouTube.

ABOUT REFEYN

Refeyn specializes in the development, production, and distribution of mass photometry solutions for industry and academia. Its innovative technology enables accurate mass measurement of single molecules in their native state without labels, delivering faster insights with minimal sample compared to conventional methods.

For more information on Refeyn, please visit www.refeyn.com or follow the company on LinkedIn or YouTube.

MEDIA CONTACTS:

Bio‑Techne
David Clair, Vice President Investor Relations
IR@bio-techne.com 

Corporate Communications
media.relations@bio-techne.com 

Refeyn
Catie Lichten
Scientific Communications Manager
catie.lichten@refeyn.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biotechne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization-302791071.html

SOURCE Bio-Techne Corporation

FAQ

What did Bio‑Techne (NASDAQ: TECH) and Refeyn announce on June 4, 2026?

Bio‑Techne and Refeyn announced an integrated workflow combining MauriceFlex™ icIEF fractionation with TwoMP mass photometry. According to Bio‑Techne, this enables direct characterization of charge, size, and aggregation in bispecific antibodies and biosimilars within a streamlined four‑hour workflow using very small sample amounts.

How does the new Bio‑Techne TECH and Refeyn workflow improve bispecific antibody characterization?

The workflow separates charge variants with MauriceFlex™ icIEF, then analyzes each fraction on Refeyn’s TwoMP mass photometry platform. According to Bio‑Techne, this links charge heterogeneity to molecular weight and aggregation at single‑molecule resolution, reducing reliance on multiple traditional assays and large sample quantities.

Why is the Bio‑Techne TECH and Refeyn workflow important for biosimilar development?

The workflow targets challenges in fully characterizing complex biosimilars and bispecific antibodies. According to Bio‑Techne, deeper characterization with less sample can help reduce development risk, control manufacturing costs, and support faster, more efficient process development to meet regulatory expectations for charge variant analysis.

What technologies power the new Bio‑Techne (TECH) and Refeyn integrated workflow?

The workflow combines Bio‑Techne’s R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation with Refeyn’s TwoMP mass photometry. According to the companies, this pairing provides high‑resolution charge variant separation plus single‑molecule assessment of size distribution and aggregation using only nanogram‑level samples.

How long does the Bio‑Techne TECH and Refeyn bispecific antibody workflow take to run?

The integrated icIEF and mass photometry workflow is designed as a four‑hour process. According to Bio‑Techne, this streamlined timeline allows researchers to correlate charge variants with size and aggregation more quickly, supporting earlier decision‑making during development and helping to accelerate biosimilar manufacturing programs.

Where was the new Bio‑Techne and Refeyn bispecific workflow demonstrated to researchers?

Scientists presented the workflow in a joint webinar using Mosunetuzumab‑axgb and a biosimilar under multiple conditions. According to Bio‑Techne, results will also be shown at the ASMS conference in San Diego, with additional details available in an application note and conference materials.